Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 -9.39%30 Quick Ratio is 19.47 as of Dec. 2025, which is 3% below its 10-year median of 20.14. GuruFocus rates ROCO:6586 with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, CHO Pharma ranks better than 91.85% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. CHO Pharma's quick ratio for the quarter that ended in Dec. 2025 was 19.47.
CHO Pharma has a quick ratio of 19.47. It generally indicates good short-term financial strength.
The historical rank and industry rank for CHO Pharma's Quick Ratio or its related term are showing as below:
ROCO:6586'
s Quick Ratio Range Over the Past 10 Years
Min: 6.39 Med: 20.14 Max: 73.05
Current: 19.47
During the past 13 years, CHO Pharma's highest Quick Ratio was 73.05. The lowest was 6.39. And the median was 20.14.
ROCO:6586's Quick Ratio is ranked better than 91.85% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ROCO:6586: 19.47
CHO Pharma (ROCO:6586) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
CHO Pharma Quick Ratio Related Terms
CHO Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for CHO Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, CHO Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where CHO Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
CHO Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) has a Quick Ratio of 19.47 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CHO Pharma and its competitors. This is near median its historical median of 20.14. Over the past decade, CHO Pharma's Quick Ratio has ranged from 6.39 to 73.05. According to the industry distribution chart, CHO Pharma ranks #115 out of 1411 companies in the Biotechnology industry, placing it in the top 8.2%.
Is CHO Pharma's Quick Ratio too high?
CHO Pharma's current Quick Ratio of 19.47 is near median its 10-year median of 20.14. Over the past 10 years, this metric has ranged from a low of 6.39 to a high of 73.05. The Biotechnology industry median Quick Ratio is 3.59. CHO Pharma's value of 19.47 is 442.3% above this industry median. Based on the distribution chart, CHO Pharma ranks #115 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CHO Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #115 out of 1411 companies for Quick Ratio. This places CHO Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. CHO Pharma's value of 19.47 is 442.3% above this benchmark. Historically, CHO Pharma's own Quick Ratio has ranged from 6.39 to 73.05 over the past decade. While the company's 10-year median is 20.14 vs. the industry median of 3.59, CHO Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHO Pharma's current Quick Ratio of 19.47 is 442.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current Quick Ratio is 19.47, which is near median its own 10-year median of 20.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Quick Ratio of 19.47. The current Quick Ratio is 19.47, which is near median its 10-year median of 20.14 and 442.3% above the Biotechnology industry median of 3.59. CHO Pharma's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Quick Ratio is 19.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
30GF Score
Get the complete analysis for ROCO:6586
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
